Advances in research on 3C-like protease (3CL<sup>pro</sup>) inhibitors against SARS-CoV-2 since 2020
Roufen Chen, Yali Gao, Han Liu, He Li, Wen‐Fa Chen, Junjie Ma
Abstract
The representative SARS-CoV-2 3CL pro inhibitors reported since 2020 and their biological activities and binding models are reviewed, providing new insights into the design and development of more effective 3CL pro inhibitors against SARS-CoV-2.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakProteaseSars virusBetacoronavirusComputational biologyMedicineBiologyEnzymeOutbreakPathologyDiseaseInfectious disease (medical specialty)BiochemistryComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies